Key patient-reported outcomes for HRQoL. Nonparametric analysis of change from baseline to month 6 during the OP and from last day of the OP to month 6 of the ATP for the Haem-A-QoL (A), EQ-5D-5L (B), and EQ-VAS (C) measures. Estimated median difference (95% CI) of marstacimab vs previous OD therapy and RP. Missing values were imputed using multiple imputation methods based on missing at random assumption.
Figure 3.

Key patient-reported outcomes for HRQoL. Nonparametric analysis of change from baseline to month 6 during the OP and from last day of the OP to month 6 of the ATP for the Haem-A-QoL (A), EQ-5D-5L (B), and EQ-VAS (C) measures. Estimated median difference (95% CI) of marstacimab vs previous OD therapy and RP. Missing values were imputed using multiple imputation methods based on missing at random assumption.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal